Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KALV Stock Summary
Top 10 Correlated ETFs
KALV
In the News
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Tim.
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Washington, DC from February 23-26. The following presentations will take place on Saturday,.
KalVista meets main goals in late-stage trial for skin condition treatment
KalVista Pharmaceuticals said on Tuesday its therapy for a type of skin condition met the main goals in a late-stage trial.
KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Japan filings expected later in 2024. Oral Factor XIIa inhibitor being advanced for patients with HAE; This could open door to target prophylactic HAE market.
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024
KalVista Pharma (NASDAQ: KALV ) just reported results for the second quarter of 2024. KalVista Pharma reported earnings per share of -80 cents.
3 Micro-Cap Stocks That Could Be Moonshots
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and under-capitalized companies, but these companies also have unique theses that should keep investors interested.
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences: Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 3:00 p.m. EST Jefferies London Healthcare Conference on Thursday, November 16, 2023 at 9:.
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Anaheim, CA from November 9-13. The presentations are: Understanding Why H.
KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista has a cash runway of about 14 months, but rising G&A costs raise concerns about capital efficiency. Given the statistically significant Phase 2 results, I speculate that the Phase 3 data, expected in Q4 2023, will likely be positive.
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
KALV Financial details
KALV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-04-30
Metric | History | 2019-04-30 | 2020-04-30 | 2021-04-30 | 2022-04-30 | 2023-04-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.07 | 0.71 | 0.66 | 0 | 0 | |
Net income per share | -1.38 | -1.64 | -2.33 | -2.8 | -2.68 | |
Operating cash flow per share | -2.41 | -2.53 | -1.58 | -3.19 | -2.7 | |
Free cash flow per share | -2.48 | -2.54 | -1.58 | -3.23 | -2.74 | |
Cash per share | 6.68 | 3.82 | 13.04 | 6.79 | 5.36 | |
Book value per share | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | |
Tangible book value per share | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | |
Share holders equity per share | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | |
Interest debt per share | -0.6 | 0.09 | 0.31 | 0.38 | -0.35 | |
Market cap | 346.86M | 193.64M | 476.79M | 311.54M | 247.39M | |
Enterprise value | 314.91M | 179.49M | 432.11M | 289M | 199.39M | |
P/E ratio | -16.66 | -6.65 | -10.72 | -4.55 | -3.31 | |
Price to sales ratio | 21.51 | 15.26 | 37.57 | 0 | 0 | |
POCF ratio | -9.54 | -4.32 | -15.8 | -3.99 | -3.29 | |
PFCF ratio | -9.26 | -4.3 | -15.76 | -3.94 | -3.24 | |
P/B Ratio | 3.59 | 2.31 | 1.85 | 1.68 | 1.54 | |
PTB ratio | 3.59 | 2.31 | 1.85 | 1.68 | 1.54 | |
EV to sales | 19.53 | 14.14 | 34.05 | 0 | 0 | |
Enterprise value over EBITDA | -10.68 | -4.53 | -7.42 | -3.06 | -1.81 | |
EV to operating cash flow | -8.66 | -4.01 | -14.32 | -3.7 | -2.65 | |
EV to free cash flow | -8.41 | -3.99 | -14.28 | -3.66 | -2.61 | |
Earnings yield | -0.06 | -0.15 | -0.09 | -0.22 | -0.3 | |
Free cash flow yield | -0.11 | -0.23 | -0.06 | -0.25 | -0.31 | |
Debt to equity | 0 | 0.02 | 0.02 | 0.04 | 0.05 | |
Debt to assets | 0 | 0.02 | 0.02 | 0.04 | 0.04 | |
Net debt to EBITDA | 1.08 | 0.36 | 0.77 | 0.24 | 0.44 | |
Current ratio | 6.4 | 11.49 | 27.04 | 16.73 | 11.46 | |
Interest coverage | 3.25 | 0 | 0 | -88.64 | 6.17 | |
Income quality | 1.75 | 1.54 | 0.65 | 0.95 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.68 | 1.03 | 1.31 | 0 | 0 | |
Research and developement to revenue | 2.17 | 3.17 | 3.25 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0 | 0 | 0.01 | 0.02 | |
Capex to revenue | -0.07 | -0.02 | -0.01 | 0 | 0 | |
Capex to depreciation | -2.86 | -0.43 | -0.15 | -1.65 | -1.67 | |
Stock based compensation to revenue | 0.18 | 0.35 | 0.56 | 0 | 0 | |
Graham number | 14.11 | 13.2 | 26.57 | 21.83 | 18.67 | |
ROIC | -0.31 | -0.46 | -0.21 | -0.4 | -0.5 | |
Return on tangible assets | -0.18 | -0.31 | -0.16 | -0.34 | -0.41 | |
Graham Net | 5.83 | 4.02 | 12.67 | 6.51 | 5.01 | |
Working capital | 97.49M | 80.98M | 254.49M | 182.07M | 157.29M | |
Tangible asset value | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M | |
Net current asset value | 94.15M | 79.92M | 249.44M | 174.86M | 150.15M | |
Invested capital | 0 | 0.02 | 0.02 | 0.04 | 0.05 | |
Average receivables | 9.07M | 13.92M | 13.47M | 12.26M | 15.33M | |
Average payables | 2.15M | 2.27M | 1.83M | 2.81M | 4.23M | |
Average inventory | 0 | 0 | 0 | 1.35M | 1.35M | |
Days sales outstanding | 256.09 | 475.36 | 299.65 | 0 | 0 | |
Days payables outstanding | 29.81K | 15.23K | 1.11K | 1.79K | 2.19K | |
Days of inventory on hand | 0 | 0 | 0 | 1.33K | 0 | |
Receivables turnover | 1.43 | 0.77 | 1.22 | 0 | 0 | |
Payables turnover | 0.01 | 0.02 | 0.33 | 0.2 | 0.17 | |
Inventory turnover | 0 | 0 | 0 | 0.27 | 0 | |
ROE | -0.22 | -0.35 | -0.17 | -0.37 | -0.46 | |
Capex per share | -0.07 | -0.01 | 0 | -0.04 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2024-01-31 for Q3
Metric | History | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 | 2024-01-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.51 | -1.17 | -0.74 | -0.8 | -0.84 | |
Operating cash flow per share | -0.33 | -0.66 | -0.78 | -0.57 | -0.79 | |
Free cash flow per share | -0.33 | -0.66 | -0.78 | -0.58 | -0.79 | |
Cash per share | 6.07 | 4.35 | 3.58 | 2.98 | 2.18 | |
Book value per share | 6.52 | 4.69 | 4.05 | 3.31 | 2.55 | |
Tangible book value per share | 6.52 | 4.69 | 4.05 | 3.31 | 2.55 | |
Share holders equity per share | 6.52 | 4.69 | 4.05 | 3.31 | 2.55 | |
Interest debt per share | 0.33 | 0.2 | 0.23 | 0.22 | 0.21 | |
Market cap | 225.1M | 304.62M | 347.58M | 293.46M | 547.59M | |
Enterprise value | 148.53M | 256.61M | 306.16M | 243.49M | 531.98M | |
P/E ratio | -3.93 | -1.9 | -3.43 | -2.65 | -4.72 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -24.23 | -13.46 | -13 | -14.8 | -19.86 | |
PFCF ratio | -24.19 | -13.42 | -13 | -14.65 | -19.85 | |
P/B Ratio | 1.22 | 1.89 | 2.49 | 2.56 | 6.18 | |
PTB ratio | 1.22 | 1.89 | 2.49 | 2.56 | 6.18 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -5.39 | -8.05 | -10.43 | -8.62 | -16.15 | |
EV to operating cash flow | -15.99 | -11.34 | -11.45 | -12.28 | -19.29 | |
EV to free cash flow | -15.96 | -11.3 | -11.45 | -12.16 | -19.28 | |
Earnings yield | -0.06 | -0.13 | -0.07 | -0.09 | -0.05 | |
Free cash flow yield | -0.04 | -0.07 | -0.08 | -0.07 | -0.05 | |
Debt to equity | 0.05 | 0.05 | 0.06 | 0.07 | 0.08 | |
Debt to assets | 0.04 | 0.04 | 0.05 | 0.06 | 0.07 | |
Net debt to EBITDA | 2.78 | 1.51 | 1.41 | 1.77 | 0.47 | |
Current ratio | 16.55 | 11.46 | 10.6 | 7.25 | 5.44 | |
Interest coverage | -36.81 | 22.3 | 0 | 0 | 0 | |
Income quality | 0.44 | 0.86 | 1.06 | 0.72 | 0.95 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.08 | -0.37 | -0.03 | -1.04 | -0.09 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.62 | 11.09 | 8.19 | 7.72 | 6.93 | |
ROIC | -0.09 | -0.27 | -0.18 | -0.23 | -0.32 | |
Return on tangible assets | -0.07 | -0.22 | -0.16 | -0.2 | -0.25 | |
Graham Net | 5.71 | 4.07 | 3.12 | 2.44 | 1.96 | |
Working capital | 180.53M | 157.29M | 135.71M | 110.86M | 84.98M | |
Tangible asset value | 184.44M | 161.03M | 139.34M | 114.45M | 88.58M | |
Net current asset value | 173.11M | 150.15M | 128.85M | 104.31M | 78.72M | |
Invested capital | 0.05 | 0.05 | 0.06 | 0.07 | 0.08 | |
Average receivables | 16.91M | 14.23M | 18.57M | 20.93M | 22.49M | |
Average payables | 2.54M | 3.26M | 4.94M | 4.98M | 4M | |
Average inventory | 0 | 0 | -10.29M | -20.93M | -10.65M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 731.2 | 1.34K | 2.29K | 2.24K | 1.35K | |
Days of inventory on hand | 0 | 0 | -9.3K | -9.73K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.12 | 0.07 | 0.04 | 0.04 | 0.07 | |
Inventory turnover | 0 | 0 | -0.01 | -0.01 | 0 | |
ROE | -0.08 | -0.25 | -0.18 | -0.24 | -0.33 | |
Capex per share | 0 | 0 | 0 | -0.01 | 0 |
KALV Frequently Asked Questions
What is KalVista Pharmaceuticals, Inc. stock symbol ?
KalVista Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol KALV
Is KalVista Pharmaceuticals, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $38. The lowest prediction is $38 and the highest is $38
What is KALV stock prediction ?
What is KalVista Pharmaceuticals, Inc. stock quote today ?
KalVista Pharmaceuticals, Inc. stock price is $11.91 today.
Is KalVista Pharmaceuticals, Inc. stock public?
Yes, KalVista Pharmaceuticals, Inc. is a publicly traded company.